Developer docs
API playgroundTry for free, no card

Search company profiles

AtriCure

Full company profile

uuid0002e8k

Namestring
AtriCure
Legal namestring
AtriCure, Inc.
Websiteurl
atricure.com
Company typeenum
Public
Founded yearint
2000
Descriptiontext

AtriCure, Inc. (NASDAQ: ATRC) is a Mason, Ohio-based medical device company founded in 2000 that develops, manufactures, and sells proprietary devices for the surgical treatment of atrial fibrillation (Afib) and post-operative pain management. The company sells directly to hospitals, cardiac surgeons, electrophysiologists, cardiologists, and anesthesia providers across North America, Europe & Middle East, Asia Pacific, and Canada/Central & South America, with over 1 million patients treated and 750,000+ AtriClip devices sold worldwide. Its revenue is generated almost entirely from hardware sales of surgical ablation systems, left atrial appendage (LAA) exclusion devices, and cryoablation probes through direct enterprise hospital sales.

AtriCure's technology portfolio spans bipolar radiofrequency ablation (Isolator Synergy clamps and pens), cryoablation (cryoICE, cryoFORM, cryoSPHERE probes), pulsed field ablation combined with RF ablation in its newly launched Dual Energy Platform, and the AtriClip family of LAA exclusion devices. The company also offers the EPi-Sense system for Hybrid AF Therapy, the only FDA-approved minimally invasive treatment for long-standing persistent AF, and Cryo Nerve Block Therapy as a non-opioid post-operative pain management approach. Supporting infrastructure includes the Multifunctional Ablation Generator (MAG), the ORLab intraoperative sensing system, and a full suite of minimally invasive surgical instruments.

The business model is a direct enterprise field sales motion targeting hospital procurement and cardiac surgery programs, supplemented by extensive physician education and training programs (in-person courses, CME-accredited modules, STS/HRS-endorsed courses), peer-to-peer surgeon training led by key opinion leaders, and patient-facing disease education through the ACT Against Afib initiative. The company operates a global commercial organization with regional offices in Amsterdam, Netherlands and Minneapolis/Minnetonka, Minnesota, and an exclusive China distribution partnership with Baheal Group established in 2018. AtriCure has been publicly traded since its 2005 IPO and reported FY2025 revenue of approximately $534.5 million (+14.9% YoY) with 75% gross margins and 12-14% growth guidance for 2026 toward a $1 billion Vision 2030 target.

Short descriptiontext

AtriCure is a publicly traded medical device company that develops and sells surgical ablation, left atrial appendage exclusion, and cryo nerve block devices used by cardiac surgeons and hospitals globally to treat atrial fibrillation and post-operative pain.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersMason, United States
HQ citystring
Mason
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac ablation devices, left atrial appendage management, cryoablation therapy systems, cardiac surgical devices, atrial fibrillation treatment
Industry5 codes
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAB
Interventional Cardiology (PCI/Structural Heart)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHADAN
Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAKALAM
Pain Management (Spine & Musculoskeletal)
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Cardiac Surgical Ablation and Left Atrial Appendage Management Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales (Surgical Ablation & LAA Management)
TypeHardware Sales
Description

AtriCure generates revenue primarily through the sale of proprietary medical devices including the AtriClip LAA exclusion system, Isolator Synergy ablation clamps, cryoICE cryoablation probes, EPi-Sense hybrid ablation systems, and related surgical instruments. The company sells directly to hospitals and cardiac surgery programs. Revenue is driven by procedure volumes in cardiac surgery (CABG, valve procedures) and growing adoption of surgical ablation and LAA management.

investing.com
Marketing channels11 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

AtriCure develops, manufactures, and sells proprietary medical devices for the surgical treatment of atrial fibrillation (Afib) and post-operative pain management. Core revenue-generating products are the AtriClip Left Atrial Appendage Exclusion System (multi-variant family including PRO-Mini, FLEX-Mini, FLEX-V, PRO-V, PRO2, PRO), the Isolator Synergy Bipolar Radiofrequency Ablation system (clamps, pens, Coolrail, Lumitip Dissection and Multifunctional Ablation Generator) for concomitant surgical ablation, the cryoICE cryoablation platform supporting Cryo Nerve Block Therapy, and the EPi-Sense based Hybrid AF Therapy for long-standing persistent AF. Products are sold directly to hospitals, cardiac surgeons, electrophysiologists, and cardiac surgery programs across more than 50 countries through a dedicated regional direct-sales organization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 9 values shown
  • Up to 90% freedom from atrial fibrillation with Cox-Maze IV surgical ablation procedure
+8 more records
Product overview1 text field

AtriCure is a medical device company offering a comprehensive portfolio of products for atrial fibrillation (Afib) treatment and post-operative pain management. The product portfolio centers on three main platforms: (1) Concomitant Surgical Ablation Therapy including Isolator Synergy bipolar RF ablation clamps and pens, Coolrail Linear Pen, and Multifunctional Ablation Generator for cardiac tissue ablation during surgery; (2) Left Atrial Appendage Management with the AtriClip family of devices (FLEX-Mini, PRO-Mini, FLEX-V, PRO-V, PRO2, PRO) for stroke prevention; and (3) Cryo Nerve Block Therapy using cryoSPHERE MAX, cryoSPHERE+, and cryoXT probes for opioid-sparing post-surgical pain management. Additional offerings include Hybrid AF Therapy combining EPi-Sense epicardial-endocardial devices for minimally invasive Afib treatment, and a Dual Energy Platform combining Pulsed Field Ablation and Radiofrequency Ablation technologies. The company also provides comprehensive minimally invasive surgical instruments. Over 750,000 patients have been served with AtriClip devices and over 1 million patients treated with ablation products worldwide.

Product and service10 records
1AtriClip Left Atrial Appendage (LAA) Exclusion System
CategoryLeft Atrial Appendage Management Devices
Description

Multi-variant family of closed-ended LAA management devices providing mechanical and electrical isolation of the left atrial appendage to reduce stroke risk in atrial fibrillation patients. The family includes AtriClip PRO, PRO2, PRO-V, PRO-Mini, FLEX, FLEX-V, and FLEX-Mini variants, designed for concomitant surgical procedures including open cardiac surgery and minimally invasive approaches; FLEX-Mini is the smallest surgical LAAM device available. Over 750,000 patients have been served with AtriClip devices worldwide.

2Isolator Synergy Bipolar Radiofrequency (RF) Ablation System
CategoryConcomitant Surgical Ablation Devices
Description

Bipolar RF ablation system for concomitant surgical ablation during cardiac surgery, including Isolator Synergy clamps (OLL2/OSL2), the Synergy EnCompass Clamp for non-atriotomy procedures, the Isolator Synergy Access Clamp for hybrid total thoracoscopic procedures, Isolator Linear Pen, Transpolar Pens (MAX1, MAX5), Coolrail Linear Pen, and the Lumitip Dissection System. Uses proprietary Synergy algorithm and energy delivery for customized RF energy output during lesion sets such as Cox-Maze IV, pulmonary vein isolation, Box lesion, and posterior wall isolation.

3Multifunctional Ablation Generator (MAG)
CategoryAblation Generators and Energy Platforms
Description

Ablation generator platform supporting multiple ablation modalities for surgical ablation procedures.

4Hybrid AF Therapy (EPi-Sense Guided Coagulation System)
CategoryHybrid Atrial Fibrillation Therapy Devices
Description

Minimally invasive two-stage solution combining epicardial and endocardial ablation for long-standing persistent atrial fibrillation. Includes the EPi-Sense device and EPi-Sense ST device (released 2023). FDA-approved for treatment of long-standing persistent AF, with hybrid ablation demonstrating up to 88% freedom from atrial arrhythmias and 94% reduction in AF burden to ≤5%, and 2x greater effectiveness than catheter ablation alone.

5Cryo Nerve Block Therapy Platform (cryoICE)
CategoryCryoablation Pain Management Devices
Description

Non-opioid post-operative pain management approach using cryoablation probes to target peripheral nerves. Includes the cryoICE BOX V6 generator and probes—cryoICE, cryoFORM, cryoSPHERE+, cryoSPHERE MAX, and cryoXT—for Cryo Nerve Block Therapy in thoracic surgery, transitional pain, amputation pain management, and cardiac tissue ablation.

6EPi-Ease Epicardial Access Device
CategoryEpicardial Access Devices
Description

Device for epicardial access supporting hybrid ablation procedures.

7ORLab System
CategoryIntraoperative Ablation Sensing and Monitoring
Description

Intraoperative system for ablation verification and monitoring during surgical ablation procedures.

8Ablation Sensing Unit & Switch Matrix
CategoryIntraoperative Ablation Sensing and Monitoring
Description

Sensing and energy delivery management equipment used during surgical ablation procedures.

9Minimally Invasive Surgical Instruments
CategoryMinimally Invasive Cardiac Surgical Instruments
Description

Suite of surgical instruments for minimally invasive cardiac procedures, including the Atrial Lift System, graspers, needle holders, retractors and blades, scissors, rakes and valve assistants, and accessories.

10Dual Energy Platform (PFA + RFA)
CategoryNext-Generation Dual Energy Ablation Platform
Description

Novel platform combining Pulsed Field Ablation (PFA) and Advanced Radiofrequency Ablation (RFA) technologies capable of ablation in less than 60 seconds. First successful treatments performed at the Victorian Heart Hospital in Australia in December 2025, with plans for a clinical trial.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Baheal Group
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-01-01
Description

AtriCure and Baheal Group established a partnership and China distribution agreement in 2018. Baheal Group serves as AtriCure's exclusive distribution partner for the China market, distributing AtriClip and cryoICE products. China represents a significant growth market for cardiac ablation and LAA management given the large Afib patient population.

openpr.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Boston Scientific is a leading competitor in atrial fibrillation treatment with its catheter-based ablation portfolio including the FARAPULSE pulsed field ablation system. It competes with AtriCure in the Afib ablation market though primarily via catheter-based rather than surgical approaches.

TypeDirect peer
Description

Medtronic is a major player in cardiac ablation through its CryoCath cryoablation and PulseSelect pulsed field ablation systems. As one of the largest medical device companies globally, it competes with AtriCure across cardiac surgery and catheter ablation for Afib.

3Abbott
TypeDirect peer
Description

Abbott competes in the Afib treatment space through its cardiac ablation portfolio and structural heart devices. It is explicitly identified as a competitive threat in the global ablation technology market alongside Medtronic, Boston Scientific, and J&J.

TypeDirect peer
Description

Biosense Webster, a Johnson & Johnson company, is a global leader in electrophysiology and catheter ablation for atrial fibrillation with the CARTO mapping system and extensive ablation catheter portfolio. It competes directly with AtriCure in the Afib ablation market.

TypeEmerging player
Description

Edwards Lifesciences has announced plans to enter the surgical left atrial appendage closure (LAAC) market in 2026, directly challenging AtriCure's AtriClip franchise. As a leading structural heart player, Edwards brings significant resources and hospital relationships.

TypeDirect peer
Description

CONMED is a medical device company with a cardiac surgery and ablation portfolio that overlaps with AtriCure's surgical ablation business. It is a smaller competitor but addresses similar hospital customers with overlapping product categories.

TypeEmerging player
Description

AngioDynamics manufactures medical devices for vascular access and ablation therapies, including NanoKnife irreversible electroporation and other ablation technologies. It competes in adjacent ablation markets with overlapping cardiology applications.

TypeEmerging player
Description

Stereotaxis develops robotic magnetic navigation systems for cardiac ablation procedures, enabling precise catheter-based ablation for arrhythmias. It represents a technology approach that competes with both catheter and surgical ablation in the Afib treatment market.

9Adagio Medical
TypeEmerging player
Description

Adagio Medical develops cryoablation technologies for atrial fibrillation, including ultra-low temperature cryoablation catheters. It is a smaller, emerging player competing in the same Afib ablation space as AtriCure's cryoablation products.

TypeEmerging player
Description

Kardium is developing the Globe PF System, a pulsed field ablation system for atrial fibrillation. As an emerging player in PFA technology, it competes with both catheter-based PFA systems and indirectly with AtriCure's emerging Dual Energy PFA+RFA platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature12 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AtriCure

Cardiac Surgical Ablation and Left Atrial Appendage Management Devicesatricure.com

AtriCure is a publicly traded medical device company that develops and sells surgical ablation, left atrial appendage exclusion, and cryo nerve block devices used by cardiac surgeons and hospitals globally to treat atrial fibrillation and post-operative pain.

What AtriCure does

AtriCure, Inc. (NASDAQ: ATRC) is a Mason, Ohio-based medical device company founded in 2000 that develops, manufactures, and sells proprietary devices for the surgical treatment of atrial fibrillation (Afib) and post-operative pain management. The company sells directly to hospitals, cardiac surgeons, electrophysiologists, cardiologists, and anesthesia providers across North America, Europe & Middle East, Asia Pacific, and Canada/Central & South America, with over 1 million patients treated and 750,000+ AtriClip devices sold worldwide. Its revenue is generated almost entirely from hardware sales of surgical ablation systems, left atrial appendage (LAA) exclusion devices, and cryoablation probes through direct enterprise hospital sales.

AtriCure's technology portfolio spans bipolar radiofrequency ablation (Isolator Synergy clamps and pens), cryoablation (cryoICE, cryoFORM, cryoSPHERE probes), pulsed field ablation combined with RF ablation in its newly launched Dual Energy Platform, and the AtriClip family of LAA exclusion devices. The company also offers the EPi-Sense system for Hybrid AF Therapy, the only FDA-approved minimally invasive treatment for long-standing persistent AF, and Cryo Nerve Block Therapy as a non-opioid post-operative pain management approach. Supporting infrastructure includes the Multifunctional Ablation Generator (MAG), the ORLab intraoperative sensing system, and a full suite of minimally invasive surgical instruments.

The business model is a direct enterprise field sales motion targeting hospital procurement and cardiac surgery programs, supplemented by extensive physician education and training programs (in-person courses, CME-accredited modules, STS/HRS-endorsed courses), peer-to-peer surgeon training led by key opinion leaders, and patient-facing disease education through the ACT Against Afib initiative. The company operates a global commercial organization with regional offices in Amsterdam, Netherlands and Minneapolis/Minnetonka, Minnesota, and an exclusive China distribution partnership with Baheal Group established in 2018. AtriCure has been publicly traded since its 2005 IPO and reported FY2025 revenue of approximately $534.5 million (+14.9% YoY) with 75% gross margins and 12-14% growth guidance for 2026 toward a $1 billion Vision 2030 target.

AtriCure firmographics

Firmographics
Name
AtriCure
Legal name
AtriCure, Inc.
Website
https://atricure.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
AtriCure is a publicly traded medical device company that develops and sells surgical ablation, left atrial appendage exclusion, and cryo nerve block devices used by cardiac surgeons and hospitals globally to treat atrial fibrillation and post-operative pain.
Ownership category
akta.pro rank

AtriCure industry classification

Industry
Product category
Cardiac Surgical Ablation and Left Atrial Appendage Management Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAB
Interventional Cardiology (PCI/Structural Heart)
SECONDARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHADAN
Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAKALAM
Pain Management (Spine & Musculoskeletal)

Keywords

  • Cardiac ablation devices
  • Left atrial appendage management
  • Cryoablation therapy systems
  • Cardiac surgical devices
  • Atrial fibrillation treatment

Where AtriCure is headquartered

Location

Headquarters

HQ city
Mason
HQ country
United States
HQ region
North America

Offices6 records

Markets served

AtriCure business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Medical Device Sales (Surgical Ablation & LAA Management): AtriCure generates revenue primarily through the sale of proprietary medical devices including the AtriClip LAA exclusion system, Isolator Synergy ablation clamps, cryoICE cryoablation probes, EPi-Sense hybrid ablation systems, and related surgical instruments. The company sells directly to hospitals and cardiac surgery programs. Revenue is driven by procedure volumes in cardiac surgery (CABG, valve procedures) and growing adoption of surgical ablation and LAA management.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels11 records

AtriCure product offering

Product offering

Core offering

AtriCure develops, manufactures, and sells proprietary medical devices for the surgical treatment of atrial fibrillation (Afib) and post-operative pain management. Core revenue-generating products are the AtriClip Left Atrial Appendage Exclusion System (multi-variant family including PRO-Mini, FLEX-Mini, FLEX-V, PRO-V, PRO2, PRO), the Isolator Synergy Bipolar Radiofrequency Ablation system (clamps, pens, Coolrail, Lumitip Dissection and Multifunctional Ablation Generator) for concomitant surgical ablation, the cryoICE cryoablation platform supporting Cryo Nerve Block Therapy, and the EPi-Sense based Hybrid AF Therapy for long-standing persistent AF. Products are sold directly to hospitals, cardiac surgeons, electrophysiologists, and cardiac surgery programs across more than 50 countries through a dedicated regional direct-sales organization.

Product overview

AtriCure is a medical device company offering a comprehensive portfolio of products for atrial fibrillation (Afib) treatment and post-operative pain management. The product portfolio centers on three main platforms: (1) Concomitant Surgical Ablation Therapy including Isolator Synergy bipolar RF ablation clamps and pens, Coolrail Linear Pen, and Multifunctional Ablation Generator for cardiac tissue ablation during surgery; (2) Left Atrial Appendage Management with the AtriClip family of devices (FLEX-Mini, PRO-Mini, FLEX-V, PRO-V, PRO2, PRO) for stroke prevention; and (3) Cryo Nerve Block Therapy using cryoSPHERE MAX, cryoSPHERE+, and cryoXT probes for opioid-sparing post-surgical pain management. Additional offerings include Hybrid AF Therapy combining EPi-Sense epicardial-endocardial devices for minimally invasive Afib treatment, and a Dual Energy Platform combining Pulsed Field Ablation and Radiofrequency Ablation technologies. The company also provides comprehensive minimally invasive surgical instruments. Over 750,000 patients have been served with AtriClip devices and over 1 million patients treated with ablation products worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

  • AtriClip Left Atrial Appendage (LAA) Exclusion System Multi-variant family of closed-ended LAA management devices providing mechanical and electrical isolation of the left atrial appendage to reduce stroke risk in atrial fibrillation patients. The family includes AtriClip PRO, PRO2, PRO-V, PRO-Mini, FLEX, FLEX-V, and FLEX-Mini variants, designed for concomitant surgical procedures including open cardiac surgery and minimally invasive approaches; FLEX-Mini is the smallest surgical LAAM device available. Over 750,000 patients have been served with AtriClip devices worldwide.
  • Isolator Synergy Bipolar Radiofrequency (RF) Ablation System Bipolar RF ablation system for concomitant surgical ablation during cardiac surgery, including Isolator Synergy clamps (OLL2/OSL2), the Synergy EnCompass Clamp for non-atriotomy procedures, the Isolator Synergy Access Clamp for hybrid total thoracoscopic procedures, Isolator Linear Pen, Transpolar Pens (MAX1, MAX5), Coolrail Linear Pen, and the Lumitip Dissection System. Uses proprietary Synergy algorithm and energy delivery for customized RF energy output during lesion sets such as Cox-Maze IV, pulmonary vein isolation, Box lesion, and posterior wall isolation.
  • Multifunctional Ablation Generator (MAG) Ablation generator platform supporting multiple ablation modalities for surgical ablation procedures.
  • Hybrid AF Therapy (EPi-Sense Guided Coagulation System) Minimally invasive two-stage solution combining epicardial and endocardial ablation for long-standing persistent atrial fibrillation. Includes the EPi-Sense device and EPi-Sense ST device (released 2023). FDA-approved for treatment of long-standing persistent AF, with hybrid ablation demonstrating up to 88% freedom from atrial arrhythmias and 94% reduction in AF burden to ≤5%, and 2x greater effectiveness than catheter ablation alone.
  • Cryo Nerve Block Therapy Platform (cryoICE) Non-opioid post-operative pain management approach using cryoablation probes to target peripheral nerves. Includes the cryoICE BOX V6 generator and probes—cryoICE, cryoFORM, cryoSPHERE+, cryoSPHERE MAX, and cryoXT—for Cryo Nerve Block Therapy in thoracic surgery, transitional pain, amputation pain management, and cardiac tissue ablation.
  • EPi-Ease Epicardial Access Device Device for epicardial access supporting hybrid ablation procedures.
  • ORLab System Intraoperative system for ablation verification and monitoring during surgical ablation procedures.
  • Ablation Sensing Unit & Switch Matrix Sensing and energy delivery management equipment used during surgical ablation procedures.
  • Minimally Invasive Surgical Instruments Suite of surgical instruments for minimally invasive cardiac procedures, including the Atrial Lift System, graspers, needle holders, retractors and blades, scissors, rakes and valve assistants, and accessories.
  • Dual Energy Platform (PFA + RFA) Novel platform combining Pulsed Field Ablation (PFA) and Advanced Radiofrequency Ablation (RFA) technologies capable of ablation in less than 60 seconds. First successful treatments performed at the Victorian Heart Hospital in Australia in December 2025, with plans for a clinical trial.

Quantifiable outcome

  • Up to 90% freedom from atrial fibrillation with Cox-Maze IV surgical ablation procedure
  • +8 more outcomes

Companies that use AtriCure

Customer profile

Named customers1 record

Segments7 records

Ideal customer profiles3 records

AtriCure technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature12 records

AtriCure partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Baheal GroupcoreChannel Partner/ Reseller/ Distributor · 1 January 2018AtriCure and Baheal Group established a partnership and China distribution agreement in 2018. Baheal Group serves as AtriCure's exclusive distribution partner for the China market, distributing AtriClip and cryoICE products. China represents a significant growth market for cardiac ablation and LAA management given the large Afib patient population.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

AtriCure competitors and assessment

Company assessment

Direct peers

  • Boston Scientific: Boston Scientific is a leading competitor in atrial fibrillation treatment with its catheter-based ablation portfolio including the FARAPULSE pulsed field ablation system. It competes with AtriCure in the Afib ablation market though primarily via catheter-based rather than surgical approaches.
  • Medtronic: Medtronic is a major player in cardiac ablation through its CryoCath cryoablation and PulseSelect pulsed field ablation systems. As one of the largest medical device companies globally, it competes with AtriCure across cardiac surgery and catheter ablation for Afib.
  • Abbott: Abbott competes in the Afib treatment space through its cardiac ablation portfolio and structural heart devices. It is explicitly identified as a competitive threat in the global ablation technology market alongside Medtronic, Boston Scientific, and J&J.
  • Johnson & Johnson (Biosense Webster): Biosense Webster, a Johnson & Johnson company, is a global leader in electrophysiology and catheter ablation for atrial fibrillation with the CARTO mapping system and extensive ablation catheter portfolio. It competes directly with AtriCure in the Afib ablation market.
  • CONMED: CONMED is a medical device company with a cardiac surgery and ablation portfolio that overlaps with AtriCure's surgical ablation business. It is a smaller competitor but addresses similar hospital customers with overlapping product categories.

Emerging players

  • Edwards Lifesciences: Edwards Lifesciences has announced plans to enter the surgical left atrial appendage closure (LAAC) market in 2026, directly challenging AtriCure's AtriClip franchise. As a leading structural heart player, Edwards brings significant resources and hospital relationships.
  • AngioDynamics: AngioDynamics manufactures medical devices for vascular access and ablation therapies, including NanoKnife irreversible electroporation and other ablation technologies. It competes in adjacent ablation markets with overlapping cardiology applications.
  • Stereotaxis: Stereotaxis develops robotic magnetic navigation systems for cardiac ablation procedures, enabling precise catheter-based ablation for arrhythmias. It represents a technology approach that competes with both catheter and surgical ablation in the Afib treatment market.
  • Adagio Medical: Adagio Medical develops cryoablation technologies for atrial fibrillation, including ultra-low temperature cryoablation catheters. It is a smaller, emerging player competing in the same Afib ablation space as AtriCure's cryoablation products.
  • Kardium: Kardium is developing the Globe PF System, a pulsed field ablation system for atrial fibrillation. As an emerging player in PFA technology, it competes with both catheter-based PFA systems and indirectly with AtriCure's emerging Dual Energy PFA+RFA platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

AtriCure social profiles

Digital presence

AtriCure financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AtriCure leadership team

Management profile

Number of profiles

Profiles6 records

AtriCure subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

AtriCure funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AtriCure M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AtriCure

What does AtriCure do?

AtriCure develops, manufactures, and sells proprietary medical devices for the surgical treatment of atrial fibrillation (Afib) and post-operative pain management. Core revenue-generating products are the AtriClip Left Atrial Appendage Exclusion System (multi-variant family including PRO-Mini, FLEX-Mini, FLEX-V, PRO-V, PRO2, PRO), the Isolator Synergy Bipolar Radiofrequency Ablation system (clamps, pens, Coolrail, Lumitip Dissection and Multifunctional Ablation Generator) for concomitant surgical ablation, the cryoICE cryoablation platform supporting Cryo Nerve Block Therapy, and the EPi-Sense based Hybrid AF Therapy for long-standing persistent AF. Products are sold directly to hospitals, cardiac surgeons, electrophysiologists, and cardiac surgery programs across more than 50 countries through a dedicated regional direct-sales organization.

Is AtriCure a public or private company?

AtriCure is a public company. It is classified as public and is currently operating.

When was AtriCure founded?

AtriCure was founded in 2000. It employs 1,001 to 5,000 people.

Where is AtriCure based?

AtriCure is headquartered in Mason, United States, in the North America region.

How does AtriCure make money?

One revenue line is on record: medical Device Sales (Surgical Ablation & LAA Management).

Who are AtriCure's main competitors?

Direct peers on record are Boston Scientific, Medtronic, Abbott, Johnson & Johnson (Biosense Webster) and CONMED. Emerging players are Edwards Lifesciences, AngioDynamics, Stereotaxis, Adagio Medical and Kardium.

Does AtriCure have an API?

No public API is recorded for AtriCure.

What industry is AtriCure in?

AtriCure's product category is Cardiac Surgical Ablation and Left Atrial Appendage Management Devices. Its primary akta.pro industry code is HLAHAFAD, Electrophysiology Mapping & Ablation Systems, with a secondary code of HLAKABAB, Interventional Cardiology (PCI/Structural Heart). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooAtriCure (ATRC) Stock Looks Fully Priced Even After Its 66% RunAtriCure shares have risen 65.9% over the past year, trading at a 4.8x P/S ratio. The Fair Ratio model suggests the current price is broadly in line with what investors pay for each dollar of sales, though the stock trades above the industry average of 2.6x.American Banking and Market NewsAtriCure (NASDAQ:ATRC) Raised to Strong-Buy at Wall Street ZenWall Street Zen upgraded AtriCure to a strong-buy rating, while other firms have mixed ratings. The company reported Q2 EPS of $0.17, beating the consensus of -$0.06, with revenue of $154.45 million. Analysts expect fiscal-year EPS of $0.44.Simply Wall StAtriCure (ATRC) Raised Guidance After A Profit Return, Is The Stock Cheap?AtriCure reported Q3 results with higher revenue and a shift to positive earnings, and raised full-year 2026 guidance. The stock trades at a double-digit discount to the average analyst target, but its P/S ratio of 4.8x exceeds the industry average of 2.9x. The article notes valuation uncertainty if international growth stalls or ablation pressure deepens.Seeking AlphaAtriCure, Inc. (ATRC) Presents at 2026 UBS Global Healthcare Conference TranscriptAtriCure's CFO Angela Wirick explained the company's evolution from a cardiac surgery Afib treatment business to minimally invasive therapies and pain management. She noted that about one-third of cardiac surgery patients have preexisting Afib, and the company now offers stand-alone Afib therapies and pain management.Seeking AlphaAtriCure: A New Quality Metric Could Put A Clip In Nearly Every Sternotomy (NASDAQ:ATRC)AtriCure is shifting from targeting AF patients to all open-heart surgery patients, aiming for broader adoption as a preventive standard of care. The company achieved GAAP profitability, with Q3 revenue up 15% year-over-year and adjusted EBITDA up 50.6%. Upcoming catalysts include the STS quality metric rollout in 2027 and BoxX-NoAF trial results in spring 2027.Defense WorldNeedham & Company LLC Forecasts Strong Price Appreciation for AtriCure (NASDAQ:ATRC) StockNeedham & Company raised its AtriCure price target to $70 from $64, keeping a Buy rating. AtriCure reported Q3 adjusted EPS of $0.17, beating the $0.06 loss estimate, and raised 2026 revenue guidance to $606–610 million. Analysts' consensus remains Hold with a $61.80 target.YahooIs AtriCure (ATRC) Fully Valued After Strong Results And Raised 2026 Guidance?AtriCure reported Q3 2026 results and raised its 2026 guidance after shifting from a loss to positive net income. The stock gained 22% over 30 days, with a fair value estimate of $68, though its P/S ratio of 5.7x exceeds the industry average of 2.8x.American Banking and Market NewsAtriCure (NASDAQ:ATRC) Given Overweight Rating at Piper SandlerPiper Sandler reaffirmed an overweight rating on AtriCure with a $70 price target, up from $60. The company reported Q3 EPS of $0.17 and revenue of $154.45 million, beating estimates. Analysts have a consensus price target of $61.80.The future of tradingAtriCure Publishes Q3 2026 Earnings Call TranscriptAtriCure reported Q3 2026 revenue of $154.5 million, up 15% year-over-year, driven by pain management, open ablation, and appendage management. Management raised full-year adjusted EBITDA guidance to $91–94 million and revenue to $606–610 million. BoxX-NoAF enrollment remains on track for year-end completion, with initial data expected in spring 2027 and FDA approval anticipated around mid-2028.TradingViewJP Morgan maintains AtriCure at Neutral, raises price target to $62 from $36JP Morgan maintained AtriCure at Neutral and raised its price target to $62 from $36, a 72.2% increase. The target implies 2.6% upside from the Nov 3 close of $60.41. Recent analyst price targets range from $68 to $70.